Cullinan Therapeutics (CGEM) Cash from Financing Activities: 2020-2024
Historic Cash from Financing Activities for Cullinan Therapeutics (CGEM) over the last 5 years, with Dec 2024 value amounting to $266.2 million.
- Cullinan Therapeutics' Cash from Financing Activities rose 100.75% to $248,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $40.8 million, marking a year-over-year increase of 257.14%. This contributed to the annual value of $266.2 million for FY2024, which is 553.21% up from last year.
- Cullinan Therapeutics' Cash from Financing Activities amounted to $266.2 million in FY2024, which was up 553.21% from $40.8 million recorded in FY2023.
- In the past 5 years, Cullinan Therapeutics' Cash from Financing Activities registered a high of $268.8 million during FY2021, and its lowest value of -$25.9 million during FY2022.
- In the last 3 years, Cullinan Therapeutics' Cash from Financing Activities had a median value of $40.8 million in 2023 and averaged $93.7 million.
- In the last 5 years, Cullinan Therapeutics' Cash from Financing Activities tumbled by 109.65% in 2022 and then soared by 553.21% in 2024.
- Cullinan Therapeutics' Cash from Financing Activities (Yearly) stood at $140.1 million in 2020, then skyrocketed by 91.80% to $268.8 million in 2021, then tumbled by 109.65% to -$25.9 million in 2022, then soared by 257.14% to $40.8 million in 2023, then soared by 553.21% to $266.2 million in 2024.